Merck KGaA will get ex-China rights to Hengrui’s PARP1 inhibitorPARP1 inhibitor, HRS-1167, as well as an option for ex-China rights to its ADC, SHR-A1904. The German major also has the option to co-promote both assets in China. Besides the upfront cash, Hengrui is eligible for up to €1.4 billion ($1.48 billion) in milestones as well as tiered royalties on net sales.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.